Medicine details

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in adult patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia.
Mobilisation of peripheral blood progenitor cells (PBPCs) in adults.
In adult patients with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
Treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in adults with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate